SCHEMBL12465666

SCHEMBL12465666

O=S(=O)(Oc1ccc2ccc3c4ccccc4ccc3c2c1)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 4/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 1/20 0.44
HTR1A P08908 4/20 0.42
HTR1D P28221 4/20 0.42
HTR1B P28222 4/20 0.42
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 2/20 0.41
HIF1A Q16665 1/20 0.41
CYP1B1 Q16678 1/20 0.41
HSD11B1 P28845 1/20 0.41
PPARG P37231 1/20 0.41
TDP1 Q9NUW8 2/20 0.38
PAX8 Q06710 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP2A6 P11509 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30290794 0.97 CA1 (0.46) HPRT1CA1CA2CA9HTR1A
SCHEMBL18133363 0.90 HTR1A (0.44) HPRT1CA1CA2CA9HTR1A
SCHEMBL2810467 0.89 HTR1D (0.47) CA1CA2CA9HTR1AHTR1D
SCHEMBL1702438 0.89 HTR1D (0.47) CA1CA2CA9HTR1AHTR1D
SCHEMBL29511664 0.89 HTR1D (0.47) CA1CA2CA9HTR1AHTR1D
SCHEMBL17548705 0.89 HTR1D (0.47) CA1CA2CA9HTR1AHTR1D
SCHEMBL10023272 0.89 HTR1D (0.47) CA1CA2CA9HTR1AHTR1D
SCHEMBL5335841 0.86 HSD11B1 (0.43) CA1CA2CA9HTR1AHTR1D
SCHEMBL23406376 0.84 HTR1D (0.44) CA1CA2CA9HTR1AHTR1D
SCHEMBL13070399 0.84 HTR1D (0.44) CA1CA2CA9HTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2670765-B1 C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY VIIV HEALTHCARE UK (NO 4) LTD (GB) 2017-10-18 EP disclosed
EP-2814834-B1 C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY VIIV HEALTHCARE UK (NO 5) LTD (GB) 2017-09-13 EP disclosed
EP-2958930-A1 C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV Bristol-Myers Squibb Company (US) 2015-12-30 EP disclosed
EP-2814834-A1 C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY Bristol-Myers Squibb Company (US) 2014-12-24 EP disclosed
WO-2014130810-A1 C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-28 WO disclosed
EP-2670765-A1 C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY Bristol-Myers Squibb Company (US) 2013-12-11 EP disclosed
WO-2013123019-A1 C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-22 WO disclosed
WO-2012106190-A1 C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-09 WO disclosed